Background: In rheumatoid arthritis (RA), little is known about clinical responses to treatment as predictors of patient-reported outcome (PRO) changes. In this post hoc analysis, we examined the relationship between clinical outcomes at week 12 and PRO changes at week 24 in patients with RA.
Methods:
In an open-label study, Latin American patients with moderate-to-severe RA and an inadequate response to methotrexate (MTX) were randomized to receive etanercept 50 mg/week plus MTX (ETN+MTX; n=281) or an additional conventional disease-modifying anti-rheumatic drug (DMARD) plus MTX (DMARD+MTX; n=142) for 24 weeks. The PROs included Health Assessment Questionnaire Disability Index (HAQ-DI), 36-item Short Form (SF-36), Physician and Patient Global Assessment scores (PGA, PtGA), Physician and Patient Satisfaction, and an activity impairment assessment. PRO changes at week 24 were calculated by week-12 improvements using the American College of Rheumatology criteria (ACR <20, ≥20 to <50, ≥50 to <70, and ≥70) and the 28-joint Disease Activity Scores (DAS28 ≥3.2, ≥2.6 to <3.2, and <2.6). Observed-cases data were analyzed using an ANCOVA model with linear contrast, adjusted for baseline PRO and ACR/DAS28 values. Results: For both ETN+MTX-and DMARD+MTX-treated patients, there was a significant linear trend between week-12 changes in ACR and DAS28 responses and week-24 changes in HAQ-DI (P<0.001 for all), with numerical improvements generally favoring ETN+MTX. Similar relationships were observed for SF-36, PGA, PtGA, Physician Satisfaction, Patient Satisfaction, and activity impairment. Conclusions: In patients with RA, clinical response after 12 weeks of treatment with ETN +MTX or DMARD+MTX could be a predictor of week-24 response for several PROs. Since patients' subjective assessment is an important factor in RA management, including treatment adherence 9 and disease remission, 10, 11 it is important to understand what kind of PRO response can be expected from a certain level of clinical response. In addition, it is of interest to assess predictive relationship between clinical and PRO improvements within a relatively short time: patients are keen to experience improvements as soon as possible, and 6 months are usually considered the maximum time for changing therapies that patients consider to be ineffective. In a randomized, open-label trial in Latin American patients with moderate-to-severe RA and an inadequate response to methotrexate (MTX) (NCT00848354), adding etanercept (ETN) to MTX was more effective than adding another conventional disease-modifying anti-rheumatic drug (DMARD), for both clinical outcomes and PROs. 12, 13 In this post hoc analysis, we used data from that trial to examine whether changes from baseline in clinical outcomes at week 12 were predictive of PRO changes at week 24.
Methods

Study Design
All study participants provided written informed consent. In addition, institutional approval was obtained from each center in which the study was conducted (see Table S1 ). Details of the 24-week, randomized phase of that study were published previously. 13 
Data Analysis
Baseline-to-week-24 PRO changes were calculated by week-12 responses on the ACR (<20, ≥20 to <50, ≥50 to <70, and ≥70) and on the DAS28 (≥3.2, ≥2.6 to <3.2, and <2.6).
Observed-cases data for ETN+MTX and DMARD+MTX groups were analyzed using ANCOVA with linear contrast, adjusted for baseline PRO and ACR/DAS28 values.
Results
Baseline Characteristics
Baseline characteristics were published previously. 13 Most of the 423 randomized patients were women (376; 89%); the average disease duration was 8.3 years (Table 1) . • African-Latin American 39 (14) 23 (16) • Other 48 (17) 20 (14) Disease duration, years, mean ± SD 8 ± 7 9 ± 8
Rheumatoid factor-positive, n (%) 242 (86) 119 (84) ESR, mm/hr, mean ± SD 43 ± 17 43 ± 16 DAS28, mean ± SD 6.6 ± 0.7 6.7 ± 0.7 HAQ Total Score, mean ± SD 1.6 ± 0.7 1.6 ± 0.7 SF-36 PCS, mean ± SD 30.2 ± 7.2 30.1 ± 6.9
HADS-Anxiety, mean ± SD 8.9 ± 4.5 9.2 ± 4.8 HADS-Depression, mean ± SD 8.0 ± 3.9 7.9 ± 4.0 PGA, mean ± SD 6.7 ± 1.6 6.7 ± 1.6
PtGA, mean ± SD 7.1 ± 2.0 7.1 ± 1.9
Note: Data from Machado et al. 
Anxiety and Depression
Overall, patients with a greater ACR or DAS28 response at week 12 also tended to experience a greater reduction in anxiety or depression at week 24, with the linear trends being significant for most depresion-related assessments (Figure 2C-D) . There was no significant linear trend in anxiety improvement by DAS28 response for any treatment ( Figure 2B ).
Global Assessments and Treatment Satisfaction
At week 24, there was an overall significant linear trend for improvement in patients' global assessment (PGA or PtGA) with an increasing level of week-12 clinical response, regardless of the add-on treatment (ETN or DMARD) (Figure 3 ). The PRO improvement generally favored ETN over DMARD, consistent with protocol-specified analyses. 13 Similar observations were made for patients' and physicians' satisfaction with treatment ( Figure 4 ). 
WPAI and Resource Utilization
There were significant linear trends for improvement in WPAI:RA subscales by ACR or DAS28 response for ETN treatment, but a low number of patients with available data precluded trend analysis for the DMARD group ( Figure S1 ). The week-24 linear trends were less clear in regard to resource utilization: the trends were significant for ETNtreated patients in terms of reduced visits to rheumatologists, other physicians, or RA-related emergency room visits by ACR, but not by DAS28 response, but there were no significant trends for DMARD treatment ( Figure S2 ).
Discussion
These data suggest that, in patients with moderate-tosevere RA and an inadequate response to MTX, PRO improvement at week 24 was proportional to clinical response at week 12. To the best of our knowledge, this is the first study that evaluated clinical outcomes as predictors of PRO response in RA. Since the treatment groups were similar in terms of baseline characteristics, and since our statistical model was adjusted for baseline PRO and ACR/DAS28 values, the significant linear trends observed are not likely to be baseline-related artifacts.
The fact that significant linear trends in PRO improvement were associated with 2 measures of clinical improvement supports the robustness of our findings. In addition, for certain PROs, significant linear trends were observed in both ETN+MTX-and DMARD+MTX-treated patients, which suggests a predictive relationship independent of the type of treatment or the novelty factor (biologic vs. conventional DMARD). In general, improvements in P < 0.001 P = 0.003 ETN-treated patients exceeded those in patients receiving DMARD, which is consistent with the prespecified analyses of these data, 13 but a trend of greater PRO improvements in patients who had experienced a greater clinical response was observed in both treatment groups. Limitations of this analysis include its post hoc nature; an open-label design, which typically limits interpretation of PRO data (patients or physicians may be more inclined to be satisfied with a novel treatment); a small number of patients available for certain outcomes (most notably WPAI:RA subscales); and the fact that PtGA is a component of DAS28, 14 so the significant linear trend observed for PtGA by DAS28 response was not surprising.
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Conclusions
In conclusion, clinical improvements could serve as predictors of certain future PRO improvements, which may be of use in clinical practice, particularly in setting treatment expectations. These findings would need to be corroborated in prospectively designed studies.
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